Key Highlights

• Abogen will receive $575 million upfront from Novartis, with potential for $7.2 billion more tied to development and approvals.

• Novartis gains exclusive rights to ABO2203 and Options to license other therapies based on Abogen's RNA technology.

• Novartis disclosed two late-stage trial failures in September that wiped nearly $30 billion from its market value.

• ABO2203 targets B cells, the immune cells that drive autoimmune conditions such as lupus and rheumatoid arthritis.

A Deal Built Around mRNA

Chinese biotech company Abogen said on Friday it has signed a licensing deal worth up to $7.8 billion with Novartis to develop therapies based on messenger RNA, underscoring the Swiss drugmaker's growing focus on an emerging class of treatments.

Under the deal, Novartis gains exclusive rights to Abogen's experimental drug, ABO2203, along with options to license other therapies based on Abogen's RNA technology. Abogen will receive $575 million upfront and could earn an additional $7.2 billion if the drug advances through development and wins regulatory approval.

How ABO2203 Works

ABO2203 is designed to treat autoimmune diseases by targeting B cells, a type of immune cell that causes disease in conditions such as lupus and rheumatoid arthritis. It uses mRNA, which is naturally present in every cell in the body, to instruct a patient's own cells to produce a treatment that destroys disease-causing B cells.

Novartis said Abogen's drug complements other treatments it is testing for autoimmune conditions, and that the ribonucleic acid technology fits its existing approach to autoimmune disease. Novartis is also advancing remibrutinib, an oral drug that recently succeeded in a late-stage multiple sclerosis study.

Investor Scrutiny of Dealmaking

The Partnership follows trial setbacks that have raised investor scrutiny of Novartis's dealmaking strategy, after setbacks with drugs acquired through previous purchases. In September, the company disclosed two late-stage trial failures that wiped nearly $30 billion from its Market Value and prompted a major Shareholder to call for tighter board oversight of future acquisitions.

Novartis said its approach to Business development has remained consistent over time. A Fund Manager who holds Novartis shares said the Abogen deal has a better risk profile because Novartis pays a smaller amount upfront to secure the rights, but added that the company does need later-stage deals with a higher level of predictability.

Novartis shares, which have recovered some of the losses triggered by the September trial setbacks, were 0.5 percent lower by 1250 GMT in a subdued European pharmaceutical sector.

mRNA Beyond Infectious Disease

In August, US drugmakers Moderna and Merck said their personalized mRNA cancer Vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, boosting confidence in the broader promise of the technology beyond infectious disease shots.

Abogen's approach uses similar mRNA technology, and the deal could help the Chinese biotech compete globally in developing treatments for hard-to-treat autoimmune diseases.

Part of a Wider Licensing Pattern

The partnership is also in line with a broader rush by rivals such as AstraZeneca and Novo Nordisk, which have licensed obesity and other treatments from companies in China.